×
0.00192162514583763 3.43147347470692E-05 -0.00420012353304505 -0.00363736188319265 -0.0059014480818064 -0.0067256880104318 -0.00823553633930421 -0.0120787866309793
Stockreport

Cancer drugs, Actelion deal boost Johnson & Johnson's revenue, earnings [CNBC]

JOHNSON & JOHNSON (JNJ)  More Company Research Source: CNBC
Last johnson & johnson earnings: 4/17 06:40 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Johnson & Johnson topped Wall Street's fourth-quarter earnings and revenue expectations with boosts from new cancer drugs and its acquisition of Swiss biotech company Actelion. Sales of blood cancer treatments Darzalex and Imbruvica surged in the quarter. Plaque psoriasis treatment Tremfya also posted strong growth, the company said, though it did not break out numbers in the earnings release. J&J projected earnings for next year that were above analysts' predictions. Here's how J&J did compared with what Wall Street expected: EPS: $1.74 vs. $1.72 per share, according to Thomson Reuters Revenue: $20.2 billion vs. $20.1 billion, according to Thomson Reuters The sprawling health company generated $20.2 billion in revenue for the quarter, an increase of 11.5 percent from the previous year. On an operational basis, J&J's revenue grew 9.4 percent. Excluding the impact of acquisitions, divestitures and currency, worldwide sales were up 4.2 percent. Included i [Read more]

IMPACT SNAPSHOT EVENT TIME: JNJ
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS